Gene therapy in nonhuman primate models of human autoimmune disease

Gene Therapy

Volumn 10, Issue 10, 2003, Pages 890-901

  t'Hart, B A ^a,c   Vervoordeldonk, M ^b   Heeney, J L ^a   Tak, P P ^b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Research and Expertise   (Netherlands)

Author keywords

Common marmoset; Mutiple sclerosis; Rhesus monkey; Rheumatoid arthritis

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA INTERFERON; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN A; DACLIZUMAB; ENDOSTATIN; FAS LIGAND; GANCICLOVIR; HLA DR ANTIGEN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LUCIFERASE; PROTEIN P40; PROTEIN P55; PROTEIN P75; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNINDEXED DRUG; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL ANIMAL; GENE TARGETING; IMMUNOMODULATION; MARMOSET; MULTIPLE SCLEROSIS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; RHEUMATOID ARTHRITIS; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ARTHRITIS; AUTOIMMUNE DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE THERAPY; GENETIC VECTORS; HAPLORHINI; HUMANS; INTERLEUKIN-4; MODELS, ANIMAL; MULTIPLE SCLEROSIS; PRIMATES;

ANIMALIA; CALLITHRIX JACCHUS; MACACA MULATTA; MARMOSETS; PRIMATES;

EID: 0038146942     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302017     Document Type: Review

References (94)

1. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-160.
2. Arnason BG. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 1996; 81: 1-11.
3. Bontrop RE, Otting N, Slierendregt BL, Lanchbury JS. Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates. Immunol Rev 1995; 143: 33-62.
4. Bontrop RE, Otting N, de Groot NG, Doxiadis GG. Major histocompatibility complex class II polymorphisms in primates. Immunol Rev 1999; 167: 339-350.
5. Toro-Goyco E, Cora EM, Kessler MJ, Martinez-Carrion M. Induction of experimental myasthenia gravis in rhesus monkeys: a model for the study of the human disease. P R Health Sci J 1986; 5: 13-18.
6. Bigazzi P, Rose N. Spontaneous autoimmune thyroiditis in animals as a model of human disease. Prog Allergy 1975; 19: 245-274.
7. Kraan MC et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998; 41: 1481-1488.
8. Rubin AS et al. Experimental arthropathy induced in rhesus monkeys (Macaca mulatta) by intradermal immunization with native bovine type II collagen. Lab Invest 1987; 57: 524-534.
9. Bakker NP et al. Experimental immune mediated arthritis in rhesus monkeys. A model for human rheumatoid arthritis? Rheumatol Int 1990; 10: 21-29.
10. Terato K et al. Sex-linked differences in susceptibility of cynomolgus monkeys to type II collagen-induced arthritis. Evidence that epitope-specific immune suppression is involved in the regulation of type II collagen autoantibody formation. Arthritis Rheum 1989; 32: 748-758.
11. Stuart J, Townes A, Ah K. Collagen autoimmune arthritis. Annu Rev Immunol 1984; 2: 199-218.
12. Bakker NP et al. Collagen-induced arthritis in an outbred group of rhesus monkeys comprising responder and nonresponder animals. Relationship between the course of arthritis and collagen-specific immunity. Arthritis Rheum 1991; 34: 616-624.
13. Anthony DD, Haqqi TM. Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: 240-244.
14. Staines NA, Wooley PH. Collagen arthritis - what can it teach us? Br J Rheumatol 1994; 33: 798-807.
15. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997; 61: 1861-1878.
16. Bakker NP et al. Resistance to collagen-induced arthritis in a nonhuman primate species maps to the major histocompatibility complex class I region. J Exp Med 1992; 175: 933-937.
17. Slierendregt BL et al. Identification of an Mhc-DPB1 allele involved in susceptibility to experimental autoimmune encephalomyelitis in rhesus macaques. Int Immunol 1995; 7: 1671-1679.
18. Turner S et al. Identification of antibody epitopes in the CB-11 peptide of bovine type II collagen recognized by sera from arthritis-susceptible and -resistant rhesus monkeys. Clin Exp Immunol 1994; 96: 275-280.
19. Hart BA, Bakker NP, Jonker M, Bontrop RE. Resistance to collagen-induced arthritis in rats and rhesus monkeys after immunization with attenuated type II collagen. Eur J Immunol 1993; 23: 1588-1594.
20. Noyori K et al. Binding characteristics of antitype II collagen antibody to the surface of diseased human cartilage as a probe for tissue damage. J Rheumatol 1994; 21: 293-296.
21. Hart BA et al. Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br J Rheumatol 1998; 37: 314-323.
22. Bakker NP et al. The anti-arthritic and immunosuppressive effects of cyclosporin A on collagen-induced arthritis in the rhesus monkey. Clin Exp Immunol 1993; 93: 318-322.
23. Brok HP et al. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol 2001; 124: 134-141.
24. van de Loo FA, van den Berg WB. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. Rheum Dis Clin North Am 2002; 28: 127-149.
25. Vervoordeldonk MJ, Tak PP. Cytokines in rheumatoid arthritis. Curr Rheumatol Rep 2002; 4: 208-217.
26. Apparailly F, Gay S, Jorgensen C. Designing novel therapeutic strategies for rheumatic diseases. Trends Immunol 2001; 22: 537-539.
27. Gouze E, Ghivizzani SC, Robbins PD, Evans CH. Gene therapy for rheumatoid arthritis. Curr Rheumatol Rep 2001; 3: 79-85.
28. Muller-Ladner U et al. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. Arthritis Rheum 1999; 42: 490-497.
29. Okamoto K et al. Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Therapy 1998; 5: 331-338.
30. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 1999; 42: 90-99.
31. Chernajovsky Y et al. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Therapy 1997; 4: 553-559.
32. Kim SH et al. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 166: 3499-3505.
33. Lozier JN et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther 2002; 13: 113-124.
34. Apparailly F et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 2002; 13: 1179-1188.
35. Pan RY et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000; 43: 289-297.
36. Conrad CK et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Therapy 1996; 3: 658-668.
37. Muller-Ladner U et al. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. J Immunol 1997; 158: 3492-3498.
38. Le CH, Nicolson AG, Morales A, Sewell KL. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene. Arthritis Rheum 1997; 40: 1662-1669.
39. Ghivizzani SC et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 1998; 95: 4613-4618.
40. Tak PP et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001; 44: 1897-1907.
41. Boyle DL et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2activity. Gene Therapy 1999; 6: 1911-1918.
42. Woods JM et al. Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther 2002; 13: 381-393.
43. Zhang H et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997; 100: 1951-1957.
44. Goossens PH et al. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys. Hum Gene Ther 1999; 10: 1139-1149.
45. Kim JM et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 2002; 46: 793-801.
46. Yin G et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002; 5: 547-554.
47. Evans CH, Ghivizzani SC, Oligino TJ, Robbins PD. Gene therapy for autoimmune disorders. J Clin Immunol 2000; 20: 334-346.
48. Evans CH et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261-1280.
49. Goossens PH et al. The effect of promoter strength in adenoviral vectors in hyperplastic synovium. Clin Exp Rheumatol 2000; 18: 547-552.
50. Lucchinetti C et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
51. Brok HP et al. Non-human primate models of multiple sclerosis. Immunol Rev 2001; 183: 173-185.
52. Genain CP, Hauser SL. Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus. Immunol Rev 2001; 183: 159-172.
53. t'Hart BA et al. A new primate model for multiple sclerosis in the common marmoset. Immunol Today 2000; 21: 290-297.
54. t'Hart BA et al. Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am J Pathol 1998; 153: 649-663.
55. Antunes SG et al. The common marmoset: a new world primate species with limited Mhc class II variability. Proc Natl Acad Sci USA 1998; 95: 11745-11750.
56. Brok HP et al. Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. J Immunol 2000; 165: 1093-1101.
57. Genain CP et al. Prevention of autoimmune demyelination in non-human primates by a cAMP- specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 1995; 92: 3601-3605.
58. Brehm U, Piddlesden SJ, Gardinier MV, Linington C. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J Neuroimmunol 1999; 97: 9-15.
59. Genain CP et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 1995; 96: 2966-2974.
60. McFarland HI et al. Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J Immunol 1999; 162: 2384-2390.
61. Blezer ELA, Brok HPM, Nicolay K, t'Hart BA. Quantifying the progressive inflammatory demyelination of brain white matter in MOG-immunized common marmosets with magnetic resonance imaging. 2002, submitted.
62. Laman JD et al. Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur J Immunol 2002; 32: 2218-2228.
63. Boon L et al. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 2001; 167: 2942-2949.
64. Constantinescu CS et al. IL-12 reverses the suppressive effect of the CD40 ligand blockade on experimental autoimmune encephalomyelitis (EAE). J Neurol Sci 1999; 171: 60-64.
65. Chang JT, Segal BM, Shevach EM. Role of costimulation in the induction of the IL-12/IL-12 receptor pathway and the development of autoimmunity. J Immunol 2000; 164: 100-106.
66. Laman JD et al. Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). J Neuroimmunol 1998; 86: 30-45.
67. Brok HP et al. Prevention of experimental autoimmune enchephalomyelitis in common marmosets using a human anti-human IL-12 mAb. J Immunol 2002; 169: 6554-6563.
68. Brok HPM et al. Immunization with MOG peptide 34-56, an immunodominant epitope in multiple sclerosis, evokes a heterogenous pattern of encephalomyelitus in an outbred group of rhesus monkeys (Macaca mulatta). 2002, submitted.
69. Jonker M et al. Autoimmunity in non-human primates: the role of major histocompatibility complex and T cells, and implications for therapy. Hum Immunol 1991; 32: 31-40.
70. Meinl E et al. Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. Am J Pathol 1997; 150: 445-453.
71. t'Hart BA, Brok HP, Amor S, Bontrop RE. The major histocompatibility complex influences the ethiopathogenesis of MS-like disease in primates at multiple levels. Hum Immunol 2001; 62: 1371-1381.
72. de Vos AF et al. Redistribution of myelin antigens from demyelinating brain lesions to antigen presenting cells within cervical lymph nodes in monkeys with experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 5415-5423.
73. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain Res Brain Res Rev 2001; 38: 140-148.
74. Dal Canto RA et al. Local delivery of cytokines by retrovirally transduced antigen-specific TCR+ hybridoma cells in experimental autoimmune encephalomyelitis. Eur Cytokine Networks 1998; 9: 83-91.
75. Shaw MK et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1997; 185: 1711-1714.
76. Chen LZ et al. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. Proc Natl Acad Sci USA 1998; 95: 12516-12521.
77. Costa GL et al. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. J Immunol 2001; 167: 2379-2387.
78. Flugel A et al. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 2001; 31: 11-22.
79. Willenborg DO, Fordham SA, Cowden WB, Ramshaw IA. Cytokines and murine autoimmune encephalomyelitis: inhibition or enhancement of disease with antibodies to select cytokines, or by delivery of exogenous cytokines using a recombinant vaccinia virus system. Scand J Immunol 1995; 41: 31-41.
80. Piccirillo CA, Prud'homme GJ. Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors. Hum Gene Ther 1999; 10: 1915-1922.
81. Croxford JL et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998; 160: 5181-5187.
82. Croxford JL, Feldmann M, Chernajovsky Y, Baker D. Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J Immunol 2001; 166: 4124-4130.
83. Furlan R et al. Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum Gene Ther 1998; 9: 2605-2617.
84. Furlan R et al. Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001; 167: 1821-1829.
85. Poliani PL et al. Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther 2001; 12: 905-920.
86. Howard MK et al. High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5. Gene Therapy 1998; 5: 1137-1147.
87. Nakajima A et al. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest 2001; 107: 1293-1301.
88. Kramer R et al. Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med 1995; 1: 1162-1166.
89. Dunbar CE. The use of nonhuman primate models to improve gene transfer into haematopoietic stem cells. J Intern Med 2001; 249: 329-338.
90. Van Beusechem VW, Valerio D. Gene transfer into hematopoietic stem cells of nonhuman primates. Hum Gene Ther 1996; 7: 1649-1668.
91. Hibino H et al. The common marmoset as a target preclinical primate model for cytokine and gene therapy studies. Blood 1999; 93: 2839-2848.
92. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Therapy 2000; 7: 20-23.
93. Dunbar C. Lentivirus get specific. Blood 2002; 99: 397.
94. Stephenson J. Studies illuminate cause of fatal reaction in gene-therapy trial. JAMA 2001; 285: 2570.